---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-027452"
form_type: "8-K"
ticker: "IMNN"
cik: "0000749647"
company_name: "Imunon, Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T19:58:52.237411+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Imunon Q2 net loss narrows to $5.6M; cash $24.1M; on track for COVID IND Q1 2024

## Summary
- Net loss Q2 2023 $5.6M ($0.61/sh) vs $6.0M ($0.87/sh) in Q2 2022; operating expenses down 10% YoY.
- Cash and investments $24.1M at June 30, 2023; plus planned $1.8M from NOL sales; expected to fund operations through 2024.
- On track to submit IND for seasonal COVID-19 vaccine (IMNN-101) in Q1 2024; FDA confirmed platform acceptability.
- Unveiled new cGMP manufacturing facility at HudsonAlpha to support R&D and lower costs.
- Preclinical data show PlaCCine vaccines elicit durable T-cell responses > 14 months, higher than mRNA vaccine.

## SEC filing metadata
- accession: 0001493152-23-027452
- form_type: 8-K
- ticker: IMNN
- cik: 0000749647
- company_name: Imunon, Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/749647/000149315223027452/0001493152-23-027452-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/749647/000149315223027452/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-027452
- JSON: https://secwatch.observer/filing/0001493152-23-027452.json
- Plain text: https://secwatch.observer/filing/0001493152-23-027452.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.